|Articles|June 1, 2015
- Applied Clinical Trials-06-01-2015
- Volume 24
- Issue 6
Applied Clinical Trials Digital Edition - June/July 2015
Regulatory: Solving Generic Cliff with 505(b)(2) The U.S. Biosimilar Pathway Trial Design: Modeling & Simulation Strategies Lifecycle Management: Bridging Economic & Clinical Value Also in this issue: EMA's Dueling Tones on Regulatory Vision Regulatory Compliance: The Site Burden Assessing Safety for Follow-on NBCDs
Advertisement
Articles in this issue
about 11 years ago
FDA Seeks Resources to Support New Research Initiativesabout 11 years ago
Safety Considerations for Follow-On Non-Biologic Complex Drugsabout 11 years ago
Putting the EMA House in Orderabout 11 years ago
Experts Call for Urgent Action on Antibiotics Researchabout 11 years ago
Oncology Leads Personalized Medicineabout 11 years ago
Characterizing the Real Cost of Site Regulatory Complianceabout 11 years ago
Using 505(b)(2) to Solve Shortfall from Generic Cliffabout 11 years ago
Lifecycle Modeling and Simulation in Clinical Trialsabout 11 years ago
The U.S. Biosimilar Pathway: Policy Precedes Scienceabout 11 years ago
Managing Portfolios for Economic and Clinical ValueAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market
2
ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation
3
ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch
4
Built-In, Not Bolted On: Why Clinical Data Security Has to Be a Design Principle
5